Shahrokh Shabahang, D.D.S., M.S., Ph.D.
Cheif Executive Officer
Dr. Shahrokh Shabahang is a co-founder and President of SEKRIS Biomedical, Inc.
Dr. Shabahang received his DDS in 1987 from University of Pacific, an endodontic certificate and MS in 1997 from Loma Linda University, and a PhD in Microbiology and Molecular Genetics from Loma Linda University in 2001.
During his tenure as a member of the faculty at Loma Linda University, he maintained a laboratory with emphasis on the effects of local infections on systemic diseases.
Starting 2005 Dr. Shabahang has dedicated his time to development of novel biological therapeutic agents from the proof-of-concept stage in the laboratory to clinical trials. His combined background in clinical practice, basic and clinical research, as well as understanding of the regulatory approval process allow Dr. Shabahang to provide a well-rounded outlook for the company.
As a co-founder, he shares the vision of translating the basic findings in the laboratory to clinical products that enable people living with inflammatory disorders to lead a free and independent life.
Leonard L. Bailey, M.D.
Chief Science Officer
Dr. Leonard Bailey developed a vision for infant heart transplantation during his residency program when he saw that otherwise perfect babies were dying from hypoplastic left heart syndrome – a congenital heart defect that defied successful reconstructive heart surgery. He performed over 200 experimental transplantations in infant research animals at Loma Linda University to determine the feasibility of transplantation in the very young before his first human transplantation in October 1984 when he transplanted a baboon heart into the infant known as Baby Fae.
In November 1985, he performed the first successful human to human heart transplantation in a newborn baby. Transplantation remains a small portion of Dr. Bailey’s practice, which involves all types of congenital heart disease in all age groups. With many scientific publications, Dr. Bailey is an internationally recognized authority on congenital heart surgery and infant heart transplantation. He lectures and operates regularly throughout the world.
He is the Distinguished Professor of Surgery of Loma Linda University School of Medicine and Surgeon-in-Chief of Loma Linda University Children’s Hospital. Dr. Bailey lives in Southern California with his wife Nancy. They have two sons.
Joachim-Friedrich Kapp, M.D., Ph.D.
Chief Medical Officer
Dr. Joachim-Friedrich Kapp joined Schering AG, Germany, in 1975 as a scientist in the Department of Inflammation Research and Immunology. He became Section Head in 1976 and Department Head in 1977.
In 1980 he transferred as Medical Director to Schering’s newly acquired US subsidiary, Berlex, and was appointed Vice President and Head of Research and Development in 1981. From 1984 through 1990 he was with Warner-Lambert’s German subsidiary Goedecke, first as Medical Director, from 1985 on as Head of Research and Development, and in 1988 he was appointed Vice President of Warner-Lambert’s International Clinical Development. In 1991, Dr. Kapp returned to Schering as President of the Global Business Unit Therapeutics.
After retiring from Schering in October 2005, Dr. Kapp has been serving on a number of Boards of Pharmaceutical and Biotech companies. Dr. Kapp is Board certified in Pharmacology and Toxicology as well as in Clinical Pharmacology.
Chief Financial Officer
Leif Eldevik is a finance and operations professional who works with early-stage and growing companies to help them manage and analyze their financial position and assist in strategic planning to promote productive financial decisions. Mr. Eldevik attended Cal State University at San Bernardino prior to taking a position as a technology analyst for a private investment firm.
After seven years as a technology analyst and equity derivatives trader, Mr. Eldevik initiated several startup businesses in the hospitality, real estate and finance industries. He has acted as a finance and business consultant in many capacities.
Most recently, Mr. Eldevik has acted as a litigation consultant and expert witness for several law firms with a focus on complex finance and forensic accounting issues. Currently, Mr. Eldevik has directed his focus and attention on the business development of early stage companies including his role as acting CFO of SEKRIS Biomedical.